Acute Coronary Sydrome: A Risky Business
A new class of anticoagulants is competing to dethrone difficult-to-manage warfarin, long the sole option in the prevention
of stroke and other bleeding complications in the 2.5 million US patients with atrial fibrillation. The novel bloodthinners
are blockers of direct factor Xa, knocking out a specific enzyme in the coagulation cascade that takes place in veins. Bayer/J&J's
Xarelto led the pack after filing data last month showing that in a Phase III trial of more than 14,000 patients, once-daily Xarelto
reduced clots by 20 percent compared to warfarin.
Asked for more data by the FDA, Xarelto lost the warfarin-replacement race to Boehringer Ingelheim's oral direct thrombin
inhibitor, Pradaxa, which was approved in October. But the $15 billion market is big enough for both new products, plus the
late-stage Factor XA inhibitors from Merck/Portola and Daiichi-Sanyko. Post-market studies will shake out the winners and
losers. Yet the recent failure of Pfizer/BMS's apixaban in Phase III due to excessive bleeding risk illustrates the tightrope
all novel anticlotting drugs must walk between efficacy and safety to get to market.
In the category of antiplatelets, which prevent blood clots in arteries, Plavix has long been king. But when the world's second-best-selling
drug goes generic next year, a flood of cheap knockoffs will raise the bar for competitors to gain market share. Proving superiority
as well as safety are the keys to the kingdom, and with 30 percent of all patients not responding to Plavix, new options are
a must. AstraZeneca's Brilinta got an OK from the FDA's advisory committee last July, but a final decision has been delayed while the agency mulls over the
anomaly of its global Phase III trial—the ADP receptor inhibitor proved superior to Plavix in reducing heart attacks, strokes,
and deaths everywhere but in the US (the leading theory is that bloodthinning aspirin is used much more widely there than
How brilliant is Brilinta's future? Consider that Lilly's Effient, the latest Plavix rival, has performed so dismally since
its 2008 launch. But Brilinta's safety profile far outshines the Lilly drug—at least so far. "Brilinta is likely to succeed
where Effient failed," says Wolters Kluwer's analyst Ben Weintraub.
In its ambition to seize control of the cardiovascular space from which some big pharmas have fled, Merck also has a big bet
on antiplatelets with its first-in-class Phase III PAR-1 thrombin receptor inhibitor, vorapaxar, whose novel mechanism of action could set it apart from Brilinta, Plavix, and other targeters of ADP receptors. Robert Hazlett,
an analyst at BMO Capital Markets, is bullish on the entire Merck cardio franchise, but especially vorapaxar, projecting $5
billion in peak annual sales.